Despite Recent Setbacks, Merck's CV Pipeline Is Strong
This article was originally published in The Pink Sheet Daily
Executive Summary
The Big Pharma reports better than expected first quarter revenues and discusses what is coming in R&D and the cardiovascular pipeline.
You may also be interested in...
Merck CEO To Street: Watch For Short-term Adaptability, Long-Term Innovation
Newly named chairman, Merck’s CEO Ken Frazier, cites several – smallish – launches, flexibility, especially in the face of setbacks, and business development, and ongoing focus on innovation as priorities in 2012 that will lead to long-term sustainability.
Merck Plans To Shed 13% Of Work Force By 2015
The pharma responds to a tough market environment by stepping up its previously-announced cost savings program to total $4 billion to $4.6 billion a year by 2015.
Merck Plans To Shed 13% Of Work Force By 2015
The pharma responds to a tough market environment by stepping up its previously-announced cost savings program to total $4 billion to $4.6 billion a year by 2015.